J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 5, Number 4, August 2013, pages 294-299

C-Reactive Protein Is Not Correlated With Endothelial Dysfunction in Overweight and Obese Women

**Table 1.** Clinical and Demographic Characteristics of Population (n = 38)
N, n: Sample number; BMI: Body mass index; WC: Waist circumference; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; ΔT: Time interval; FMV: Flow-mediated mean velocity in reactive hiperemia; FMD: Flow-mediated vasodilation; ΔFMD: Absolute difference between arterial basal diameter and arterial diameter after reactive hiperemia. ^aN = 37; ^bN = 36; ^cN = 35; ^dN = 33.
Age (years)	53.61 ± 11.61
Education Level^a
Illiterate, n (%)	1 (2.7%)
Complete First grade	16 (42.1%)
Complete Second grade	19 (50%)
Incomplete superior	1 (2.7%)
Skin Color^b
White, n (%)	4 (10.52%)
Non-White, n (%)	34 (86.8%)
Smoking^b
Non smoker, n (%)	36 (100%)
BMI^a, kg/m²	32.37 ± 5.06
WC^b, cm	104.833 ± 10.64
SBP^a, mmHg	134.19 ± 17.435
DBP^a, mmHg	86.16 ± 10.69
MBP^a, mmHg	102.2 ± 11.8
Medication use
Antihipertensives^c, n (%)	25 (71.4%)
Hipoglycemiants^d, n (%)	13 (39.4%)
Lipid lowering agents^d, n (%)	14 (42.4%)
CRP, mg/L, median/interquartile range	2.59/4.26
FMV, cm/s	55.92 ± 24.84
FMD (%)	8.75% ± 5.22%
ΔFMD	0.302 ± 0.174

Table 1. Clinical and Demographic Characteristics of Population (n = 38)

N, n: Sample number; BMI: Body mass index; WC: Waist circumference; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; ΔT: Time interval; FMV: Flow-mediated mean velocity in reactive hiperemia; FMD: Flow-mediated vasodilation; ΔFMD: Absolute difference between arterial basal diameter and arterial diameter after reactive hiperemia. ^aN = 37; ^bN = 36; ^cN = 35; ^dN = 33.

Age (years)

53.61 ± 11.61

Education Level^a

Illiterate, n (%)

1 (2.7%)

Complete First grade

16 (42.1%)

Complete Second grade

19 (50%)

Incomplete superior

1 (2.7%)

Skin Color^b

White, n (%)

4 (10.52%)

Non-White, n (%)

34 (86.8%)

Smoking^b

Non smoker, n (%)

36 (100%)

BMI^a, kg/m²

32.37 ± 5.06

WC^b, cm

104.833 ± 10.64

SBP^a, mmHg

134.19 ± 17.435

DBP^a, mmHg

86.16 ± 10.69

MBP^a, mmHg

102.2 ± 11.8

Medication use

Antihipertensives^c, n (%)

25 (71.4%)

Hipoglycemiants^d, n (%)

13 (39.4%)

Lipid lowering agents^d, n (%)

14 (42.4%)

CRP, mg/L, median/interquartile range

2.59/4.26

FMV, cm/s

55.92 ± 24.84

FMD (%)

8.75% ± 5.22%

ΔFMD

0.302 ± 0.174

**Table 2.** Assessment of Endothelial Function, in Groups Dichotomized at the Median Value of CRP
	CRP ≥ 2.59	CRP < 2.59	P
FMD: Flow-mediated vasodilation; ΔFMD: Absolute difference between arterial basal diameter and arterial diameter after reactive hiperemia. FMV: Flow-mediated mean-Speedity in reactive hyperemia.
FMV, cm/s	60 ± 24.6	51.01 ± 24.7	0.2
FMD	9.2 ± 4.9%	8.3 ± 5.6%	0.6
ΔFMD, mm	0.33 ± 0.16	0.28 ± 0.18	0.4

Table 2. Assessment of Endothelial Function, in Groups Dichotomized at the Median Value of CRP

CRP ≥ 2.59

CRP < 2.59

FMD: Flow-mediated vasodilation; ΔFMD: Absolute difference between arterial basal diameter and arterial diameter after reactive hiperemia. FMV: Flow-mediated mean-Speedity in reactive hyperemia.

FMV, cm/s

60 ± 24.6

51.01 ± 24.7

0.2

FMD

9.2 ± 4.9%

8.3 ± 5.6%

0.6

ΔFMD, mm

0.33 ± 0.16

0.28 ± 0.18

0.4

**Table 3.** Comparison of Serum CRP Level on Individuals Who Use Drugs or Not
	Drugs yes CRP (mg/L)	Drugs not CRP (mg/L)	P
Antihypertensives	2.60	1.565	0.75
Lipid-lowering agents	2.42	3.34	0.17
Hypoglycemiants	3.28	2.61	0.19

Table 3. Comparison of Serum CRP Level on Individuals Who Use Drugs or Not

Drugs yes
CRP (mg/L)

Drugs not
CRP (mg/L)

Antihypertensives

2.60

1.565

0.75

Lipid-lowering agents

2.42

3.34

0.17

Hypoglycemiants

3.28

2.61

0.19

**Table 4.** Comparison Between Endothelial Function Variables in Individuals Using Medications or Not
	Yes	No	P
FMD: Flow-mediated vasodilation; ΔFMD: Absolute difference between arterial basal diameter and arterial diameter after reactive hiperemia. FMV: Flow-mediated mean-Speedity in reactive hyperemia.
Antihypertensives
FMV, cm/s	54.88	55.55	0.95
FMD	8.84%	8.40	0.83
ΔFMD, mm	0.3	0.32	0.79
Lipid-lowering agents
FMV, cm/s	51.97	54.58	0.76
FMD	9.77%	8.67%	0.57
ΔFMD, mm	0.34	0.30	0.65
Hypoglycemiants
FMV, cm/s	55.65	52.06	0.68
FMD	10.31%	8.37%	0.32
ΔFMD, mm	0.33	0.31	0.77

Table 4. Comparison Between Endothelial Function Variables in Individuals Using Medications or Not

Yes

FMD: Flow-mediated vasodilation; ΔFMD: Absolute difference between arterial basal diameter and arterial diameter after reactive hiperemia. FMV: Flow-mediated mean-Speedity in reactive hyperemia.

Antihypertensives

FMV, cm/s

54.88

55.55

0.95

FMD

8.84%

8.40

0.83

ΔFMD, mm

0.3

0.32

0.79

Lipid-lowering agents

FMV, cm/s

51.97

54.58

0.76

FMD

9.77%

8.67%

0.57

ΔFMD, mm

0.34

0.30

0.65

Hypoglycemiants

FMV, cm/s

55.65

52.06

0.68

FMD

10.31%

8.37%

0.32

ΔFMD, mm

0.33

0.31

0.77